<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar major depression in adults: Investigational and nonstandard approaches to treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar major depression in adults: Investigational and nonstandard approaches to treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar major depression in adults: Investigational and nonstandard approaches to treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William V Bobo, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard C Shelton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3684995993"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bipolar disorder is marked by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and nearly always includes episodes of major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Observational studies consistently show that depressive episodes predominate the clinical course of bipolar disorder [<a href="#rid2">2,3</a>]. Compared with manic and hypomanic episodes, bipolar depressive episodes and residual bipolar depressive symptoms account for a greater proportion of long-term morbidity, impaired functioning, and risk of suicide [<a href="#rid4">4,5</a>].</p><p>As a result, improved treatment of major depression is a patient priority. An internet-based survey from 11 countries, which asked patients with bipolar disorder (n = 1300) which aspects of care they would most like to see improved, better treatment of depression was endorsed by the largest number (&gt;40 percent) [<a href="#rid6">6</a>]. The second and third leading aspects of care that patients would most like to see improved were avoiding weight gain and preventing relapse of depressive episodes.</p><p>This topic reviews investigational approaches to treating bipolar major depression in adults. Other topics discuss choosing treatment for adults with bipolar major depression, the general principles of treating bipolar major depression in adults, the efficacy and adverse effects of antidepressants and second-generation antipsychotics for bipolar major depression in adults, choosing pharmacotherapy for adults with acute mania and hypomania, choosing maintenance treatment for adults, and choosing pharmacotherapy for pediatric bipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3514714294"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by periods of pathologic mood elevation (mania or hypomania) [<a href="#rid1">1</a>]. Patients with bipolar I disorder experience manic episodes  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>) and nearly always experience both hypomanic episodes  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and major depressive episodes  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>). Bipolar II disorder is marked by at least one episode of hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>), and one or more major depressive episodes. In addition, psychotic features such as delusions and hallucinations frequently accompany bipolar depressive episodes, particularly in patients with bipolar I disorder [<a href="#rid7">7</a>].</p><p>Additional information about the clinical features and diagnosis of bipolar disorder, including bipolar major depression, is discussed separately. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis"</a>.)</p><p class="headingAnchor" id="H3669272120"><span class="h1">INVESTIGATIONAL AND NONSTANDARD APPROACHES</span><span class="headingEndMark"> — </span>Investigational and nonstandard approaches for bipolar major depression include [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">Armodafinil</a> and <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a></p><p class="bulletIndent1"><span class="glyph">●</span>Bright light therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Chronotherapy</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">Levothyroxine</a> (T4)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">Methylene blue</a></p><p class="bulletIndent1"><span class="glyph">●</span>N-acetyl cysteine</p><p class="bulletIndent1"><span class="glyph">●</span>Omega-3 fatty acids</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9560" href="/d/drug information/9560.html" rel="external">Pramipexole</a></p><p></p><p>These treatments are typically not used due to limited evidence of their efficacy, safety, and tolerability. As an example, some of the treatments have been investigated in small samples or only one trial, and the results need to be replicated before we can suggest using them routinely. For other treatments, the evidence of efficacy was inconsistent, such that some studies indicated the treatment was helpful and other studies did not. Another problem with the treatments is the lack of longer (eg, ≥8 weeks) trials to evaluate the benefits and risks; maintenance treatment generally consists of the regimen used for initial treatment. Some studies were problematic in that they analyzed study completers (per protocol analysis), which can potentially bias the results, rather than analyzing all patients who were randomized (intent to treat analysis).</p><p>The investigational treatments have typically been studied as add-on treatments in patients who did not respond to standard drugs such as second-generation antipsychotics (eg, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> or <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>), <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and antidepressants.</p><p class="headingAnchor" id="H1599907230"><span class="h2">Armodafinil and modafinil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">Modafinil</a> consists of two stereoisomers that are mirror images of each other and thus not identical in that they cannot be superimposed upon each other (similar to one’s hands). One of the stereoisomers is R-modafinil (<a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a>).</p><p>Multiple randomized trials suggest that short-term augmentation with <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> and <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> may provide a small benefit for patients with bipolar I or II major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of two trials, lasting six or eight weeks, compared add-on <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> (150 mg/day) or <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> (200 mg/day) with placebo in 342 patients [<a href="#rid9">9</a>]. Improvement was greater with armodafinil/modafinil than placebo, and the clinical benefit was small to moderate. In addition, safety, tolerability, and adverse effects were comparable for active treatment and placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent eight-week trial compared add-on <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> (150 mg/day) with placebo in 393 patients and found that response (reduction of baseline symptoms ≥50 percent) occurred in more patients with armodafinil (56 versus 46 percent) [<a href="#rid10">10</a>]. Discontinuation of treatment due to adverse effects was comparable with armodafinil and placebo (5 and 4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another subsequent eight-week trial compared add-on <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> (150 mg/day) with placebo in 393 patients and found that response occurred in more patients with armodafinil (46 versus 34 percent) [<a href="#rid11">11</a>]. Discontinuation of treatment due to adverse effects was comparable with armodafinil and placebo (4 and 5 percent).</p><p></p><p>However, another eight-week randomized trial in 454 patients with bipolar major depression found that the rate of response to add-on treatment with <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> (150 mg/day) or placebo was similar (40 and 39 percent) [<a href="#rid12">12</a>]. In addition, other randomized trials that compared adjunctive armodafinil with placebo for bipolar depression found that the benefit was comparable for the primary outcome [<a href="#rid11">11</a>].</p><p class="bulletIndent1">Augmentation with <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> and <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a> for unipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/14676.html" rel="external">"Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs", section on 'Modafinil and armodafinil'</a>.)</p><p></p><p class="headingAnchor" id="H1399782689"><span class="h2">Bright light therapy</span><span class="headingEndMark"> — </span>Based upon randomized trials, augmentation with bright light therapy may perhaps help bipolar patients with nonseasonal major depression [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A six-week trial enrolled patients with bipolar I or II major depression who had not responded to pharmacotherapy and randomly assigned them to adjunctive bright light therapy (7000 lux) or placebo (dim red light, 50 lux) [<a href="#rid14">14</a>]. Patients with seasonal affective disorder were not excluded; seasonality traits were present in more than 80 percent of patients, and nearly 75 percent were enrolled during the fall and winter. Bright light therapy or placebo were administered at midday and the target dose was 60 minutes per day by week 4. Among the patients who completed at least one study visit between weeks 4 and 6 (n = 40), remission was greater with add-on bright light therapy than placebo (68 versus 22 percent). In addition, functioning improved more with bright light therapy. None of the study patients switched polarity. However, the study results may have been biased because the analyses included only the patients who completed at least one study visit between weeks 4 and 6 (n = 40), rather than all of the patients who were initially randomized (n = 46).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A two-week trial enrolled patients with bipolar major depression who had not responded to pharmacotherapy and randomly assigned them to adjunctive bright light therapy (5000 lux) or placebo (dim red light, &lt;100 lux) [<a href="#rid15">15</a>]. Patients with seasonal affective disorder were not excluded, and seasonality traits were not assessed; both inpatients and outpatients were included. Add-on study treatments were administered in the morning for 60 minutes. Among the patients who completed the study (n = 63), response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received bright light therapy than placebo (79 versus 43 percent). One patient in each group became more irritable, but otherwise no manic symptoms emerged, and the treatment was well tolerated. However, the study results may have been biased because the analyses included only the patients who completed the study (n = 63), rather than all of the patients who were initially randomized (n = 74).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another two-week trial, investigators enrolled patients with nonseasonal bipolar major depression (n = 50) or unipolar major depression (n = 45) who had not responded to pharmacotherapy and randomly assigned them to adjunctive bright light therapy (10,000 lux) or placebo (sham negative ion generator) [<a href="#rid16">16</a>]. Add-on study treatments were administered in the morning for 30 minutes. Remission occurred in more patients who received bright light therapy than placebo (29 versus 12 percent), and the benefit of active treatment was comparable for bipolar depression and unipolar depression.</p><p></p><p>By contrast, one study found that bright light therapy was not beneficial for bipolar major depression. An eight-week randomized trial compared bright light therapy (7000 lux) with a placebo control (low density negative ion therapy) as add-on treatment in 38 patients with bipolar I or II depression who were treated pharmacotherapy; study treatments were administered for 7.5 to 45 minutes upon awakening [<a href="#rid17">17</a>]. Improvement in the two groups was comparable. However, the duration of exposure to bright light therapy may have been subtherapeutic, based upon studies in bipolar patients with seasonal affective disorder and patients with nonseasonal unipolar major depression.</p><p>Separate topics discuss the efficacy and administration of bright light therapy for seasonal affective disorder, including bipolar disorder with seasonal pattern, and the efficacy of bright light therapy for nonseasonal unipolar major depression. (See  <a class="medical medical_review" href="/d/html/101250.html" rel="external">"Seasonal affective disorder: Treatment"</a> and  <a class="medical medical_review" href="/d/html/90155.html" rel="external">"Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Bright light therapy'</a>.)</p><p class="headingAnchor" id="H2989654358"><span class="h2">Chronotherapy</span><span class="headingEndMark"> — </span>Short-term augmentation with chronotherapy may perhaps improve symptoms of bipolar depression. A seven-week randomized trial compared chronotherapy plus pharmacotherapy with pharmacotherapy alone in patients with bipolar major depression (n = 49) [<a href="#rid18">18</a>]. Chronotherapy consisted of sleep deprivation for one night, bright light therapy (5000 lux for two hours) for three days, and sleep phase advancement (progressively later sleep initiation time) over three nights. Pharmacotherapy included mood stabilizers (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>) plus antidepressants (eg, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>). Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received chronotherapy plus pharmacotherapy than pharmacotherapy alone (59 versus 22 percent). Two patients treated with chronotherapy switched to hypomania, which resolved within one day without additional medication.</p><p class="headingAnchor" id="H3887584239"><span class="h2">Ketamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> is a standard anesthetic drug that may be effective for short-term treatment of bipolar major depression [<a href="#rid19">19</a>]. A meta-analysis of two small randomized trials compared add-on intravenous ketamine (0.5 mg/kg) with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (placebo) in 33 patients who were hospitalized for treatment-resistant bipolar I or II major depression and treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid20">20</a>]. Study drugs were administered as a single infusion. Response (reduction of baseline symptoms ≥50 percent) at 24 hours was nearly 12 times more likely with ketamine than placebo (odds ratio 11.6, 95% CI 1.3-107.7). At 72 hours, response was eight times more likely with ketamine, but the difference between the two study drugs was no longer statistically significant. A second meta-analysis of the same two trials also found that improvement of depression was greater with ketamine than placebo, and the clinical benefit was large [<a href="#rid21">21</a>].</p><p>Transient side effects that occurred only with <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> in the two trials included dissociation, feeling strange or bizarre, tachycardia, and increased blood pressure [<a href="#rid22">22</a>], as well as difficulty falling asleep and dizziness or faintness [<a href="#rid23">23</a>]. Among the 33 patients, switching to mania/hypomania occurred in one patient during infusion with placebo [<a href="#rid22">22</a>].</p><p>In addition, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> may be effective specifically for short-term management of suicidal ideation in bipolar disorder. A six-week randomized trial compared add-on ketamine (0.5 mg/kg) with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> in 52 patients with bipolar disorder who required hospitalization for suicidal ideation in the context of moderate to severe depression [<a href="#rid24">24</a>]. Study drugs were administered intravenously at baseline and at 24 hours, in conjunction with daily antipsychotics, antiepileptics, anxiolytics, and/or antidepressants. At day 3, remission of suicidal ideas occurred in more patients treated with ketamine than placebo (85 versus 28 percent), and the benefit appeared to persist at week 6. Throughout the study, ketamine was well tolerated and none of the study patients developed mania. However, by week 6, the rate of suicide attempts in the ketamine and placebo arms was comparable (8 and 10 percent).</p><p>Information about the investigational use of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> for unipolar major depression and suicidal ideation is discussed separately. (See  <a class="medical medical_review" href="/d/html/119992.html" rel="external">"Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects"</a>.)</p><p class="headingAnchor" id="H4106901515"><span class="h2">Levothyroxine (T4)</span><span class="headingEndMark"> — </span>Supraphysiologic doses of adjunctive <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> may be useful for bipolar major depression. A six-week randomized trial compared add-on levothyroxine (300 mcg/day) with placebo in 62 patients with bipolar I or II major depression who had not responded to current pharmacotherapy (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, and antidepressants) [<a href="#rid25">25</a>]. The mean change in depression rating scale scores from randomization to week 6 was larger with add-on levothyroxine than placebo. However, several other outcome measures, such as the amount of improvement at week 6 and the number of patients who responded or remitted, were comparable for the two groups. Three patients receiving active drug discontinued treatment due to adverse effects (mild thyrotoxicosis, rash, and switch to mania), compared with none of the patients receiving placebo.</p><p>Use of supraphysiologic doses of adjunctive <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> for rapid cycling bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression", section on 'Refractory patients'</a> and  <a class="medical medical_review" href="/d/html/16847.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania", section on 'Refractory patients'</a>.)</p><p class="headingAnchor" id="H1066617815"><span class="h2">Methylene blue</span><span class="headingEndMark"> — </span>Two small, randomized crossover trials suggest that adjunctive <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> may help bipolar patients with depressive symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>One trial compared an active dose of <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> (300 mg/day) with low-dose methylene blue (15 mg/day, “placebo”) as add-on therapy in 17 patients with bipolar disorder [<a href="#rid26">26</a>]. At study entry, all patients were on <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and some were receiving other medications. Patients were randomly assigned to active dose or low-dose methylene blue for one year and then crossed over to the other dose for another year. Throughout the two years, the mean number of weeks depressed was less during treatment with active dose methylene blue than low dose (10 versus 19 weeks), whereas the number of weeks manic was comparable. In addition, a combined measure of severity and duration of depressive and manic illness indicated the active dose was superior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent trial compared a therapeutic dose of <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> (195 mg/day) with a subtherapeutic dose of methylene blue (15 mg/day) as add-on therapy in 37 patients with bipolar I or II disorder [<a href="#rid27">27</a>]. At study entry, all patients were partially stabilized with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, with or without other mood stabilizers. Patients were randomly assigned to a therapeutic or subtherapeutic dose of methylene blue for 13 weeks and then crossed over to the other dose for another 13 weeks (patients thus served as their own controls). Residual depressive symptom scores were lower during treatment with the therapeutic dose than the subtherapeutic dose, regardless of the order of treatment, and the clinical effect of the therapeutic dose was moderate to large. In addition, symptoms of anxiety were lower with the therapeutic dose. Manic/hypomanic symptoms remained low throughout the entire study. Methylene blue was well tolerated, and the most common adverse effects were burning urination, diarrhea, headaches, and nausea.</p><p></p><p><a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">Methylene blue</a> may be difficult to mask (blind) because it can cause a blue or green tint to urine, feces, or sweat.</p><p class="headingAnchor" id="H2063439628"><span class="h2">N-acetyl cysteine</span><span class="headingEndMark"> — </span>The benefit of augmentation with <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC) for treating bipolar depression is not clear. A meta-analysis of five randomized trials compared add-on NAC (1 to 3 grams daily) with placebo in 335 patients acutely ill with bipolar I or II depression, and found that improvement was comparable in the two groups [<a href="#rid28">28</a>]. However, three of the trials (total n = 197) lasted only 16 or 20 weeks, which may not be a sufficient length of treatment. A 24-week randomized trial compared add-on NAC (1 gram twice daily) with placebo in 75 patients with bipolar I or II disorder [<a href="#rid29">29</a>]. On average, the patients were mildly to moderately depressed, such that symptoms did not reach the threshold for major depression. Improvement was greater with NAC than placebo; the superiority of NAC first became apparent at week 20 and became more robust at week 24.</p><p class="headingAnchor" id="H2570458216"><span class="h2">Neuromodulation</span><span class="headingEndMark"> — </span>Several neuromodulation procedures for treating bipolar major depression have been investigated, including noninvasive therapies such as repetitive transcranial magnetic stimulation, as well as invasive procedures such as deep brain stimulation. (See  <a class="medical medical_review" href="/d/html/86502.html" rel="external">"Bipolar disorder in adults: Overview of neuromodulation procedures"</a>.)</p><p>Neuromodulation in the form of electroconvulsive therapy is a standard treatment for bipolar disorder, including bipolar major depression. (See  <a class="medical medical_review" href="/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy"</a>.)</p><p class="headingAnchor" id="H874816008"><span class="h2">Omega-3 fatty acids</span><span class="headingEndMark"> — </span>Dietary supplementation with omega-3 fatty acids (n-3 polyunsaturated fatty acids) from fish oils may have modest to moderate benefits for bipolar depression. Given the available data for bipolar depression, other health benefits, and the apparent lack of serious adverse effects, use of omega-3 fatty acids (eg, 1 to 2 grams per day) as an adjunctive treatment is reasonable in patients with bipolar depression, particularly those with increased cardiovascular risk who might also benefit from the effects on elevated triglycerides. (See  <a class="medical medical_review" href="/d/html/5365.html" rel="external">"Fish oil: Physiologic effects and administration"</a> and  <a class="medical medical_review" href="/d/html/4561.html" rel="external">"Lipid management with diet or dietary supplements"</a>.)</p><p>Low-quality, direct evidence supporting the use of adjunctive omega-3 fatty acids for bipolar depression includes a meta-analysis of five randomized trials that compared add-on omega-3 fatty acids with placebo in patients with bipolar I or II disorder (n = 291), including one trial in children (mean age = 13 years; n = 51) [<a href="#rid30">30</a>]. In four trials, omega-3 fatty acids consisted of eicosapentaenoic acid alone or combined with docosahexaenoic acid; one trial used flaxseed oil with alpha-linolenic acid. The trials lasted 12 or 16 weeks. Improvement was greater with omega-3 fatty acids than placebo, and the clinical effect was small to moderate.</p><p>Indirect evidence that suggests omega-3 fatty acids may help patients with bipolar depression includes a meta-analysis of 25 randomized trials that compared omega-3 fatty acids with placebo in 1373 patients with unipolar major depression and found a small but statistically significant advantage for active drug [<a href="#rid31">31</a>]. However, the investigators concluded that the effect was probably not clinically meaningful. In addition, heterogeneity across studies was substantial, and it was likely that publication bias skewed the analysis towards finding a beneficial effect for omega-3 fatty acids. Additional information about the use of omega-3 fatty acids for unipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/90155.html" rel="external">"Unipolar depression in adults: Investigational and nonstandard treatment", section on 'Omega-3 fatty acids'</a>.)</p><p class="headingAnchor" id="H1182554717"><span class="h2">Pramipexole</span><span class="headingEndMark"> — </span>Two small randomized trials suggest that adjunctive <a class="drug drug_general" data-topicid="9560" href="/d/drug information/9560.html" rel="external">pramipexole</a> may perhaps improve bipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>A six-week trial compared add-on <a class="drug drug_general" data-topicid="9560" href="/d/drug information/9560.html" rel="external">pramipexole</a> (average dose 1.7 mg/day) with placebo in 21 patients with bipolar II major depression, and found that response (reduction of baseline symptoms &gt;50 percent) occurred in more patients who received pramipexole (6/10 versus 1/11 [60 versus 9 percent]) [<a href="#rid32">32</a>]. Adverse effects in the two groups were comparable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another six-week trial compared add-on <a class="drug drug_general" data-topicid="9560" href="/d/drug information/9560.html" rel="external">pramipexole</a> (average dose 1.7 mg/day) with placebo in 22 patients with bipolar I or II major depression and found that response occurred in more patients who received pramipexole (8/12 versus 2/10 [67 versus 20 percent]) [<a href="#rid33">33</a>]. Adverse effects in the two groups were comparable.</p><p></p><p>Augmentation with <a class="drug drug_general" data-topicid="9560" href="/d/drug information/9560.html" rel="external">pramipexole</a> for unipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/14676.html" rel="external">"Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs", section on 'Pramipexole'</a>.)</p><p class="headingAnchor" id="H2323306338"><span class="h1">TREATMENTS WITH LITTLE TO NO BENEFIT</span><span class="headingEndMark"> — </span>Randomized trials in patients with bipolar major depression suggest that the following drugs provide little to no benefit:</p><p class="bulletIndent1"><span class="glyph">●</span>Agomelatine [<a href="#rid34">34</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">Celecoxib</a> [<a href="#rid35">35,36</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cytidine [<a href="#rid20">20</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> [<a href="#rid37">37</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> [<a href="#rid38">38</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">Levetiracetam</a> [<a href="#rid39">39</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10143" href="/d/drug information/10143.html" rel="external">Lisdexamfetamine</a> [<a href="#rid40">40</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> [<a href="#rid20">20</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">Minocycline</a> [<a href="#rid36">36</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnenolone [<a href="#rid41">41</a>]</p><p></p><p>However, some of the trials were underpowered. As an example, the trial that compared <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> with placebo included only 28 patients [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2309893764"><span class="h1">CHOOSING TREATMENT</span><span class="headingEndMark"> — </span>Choosing a specific treatment regimen for acute episodes of bipolar I or II major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H2238969802"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H259347046"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2398853889"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Investigational and nonstandard treatments for bipolar major depression include <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a> and <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>, bright light therapy, chronotherapy, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> (T4), <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>, N-acetyl cysteine, neuromodulation, and <a class="drug drug_general" data-topicid="9560" href="/d/drug information/9560.html" rel="external">pramipexole</a>. These treatments are typically not used due to limited evidence of their efficacy, safety, and tolerability. (See <a class="local">'Investigational and nonstandard approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other investigational treatments for bipolar major depression include omega-3 fatty acids. Omega-3 fatty acids (eg, 1 to 2 grams per day) are a reasonable adjunctive treatment for patients with bipolar depression, given the available data for bipolar depression, their other health benefits, and apparent lack of serious adverse effects. (See <a class="local">'Omega-3 fatty acids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs that appear to provide little to no benefit in treating bipolar major depression include agomelatine, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, cytidine, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>, <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="10143" href="/d/drug information/10143.html" rel="external">lisdexamfetamine</a>, <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, and pregnenolone. (See <a class="local">'Treatments with little to no benefit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are several standard treatment options for patients with bipolar major depression. (See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.</a></li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.</a></li><li><a class="nounderline abstract_t">Simon GE, Bauer MS, Ludman EJ, et al. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007; 68:1237.</a></li><li><a class="nounderline abstract_t">Rihmer Z. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2005; 2:48.</a></li><li><a class="nounderline abstract_t">McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009; 70 Suppl 3:5.</a></li><li><a class="nounderline abstract_t">Goes FS, Sadler B, Toolan J, et al. Psychotic features in bipolar and unipolar depression. Bipolar Disord 2007; 9:901.</a></li><li><a class="nounderline abstract_t">Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387:1561.</a></li><li><a class="nounderline abstract_t">Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013; 74:1101.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Frye MA, Yang R, et al. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Psychiatry 2014; 75:1054.</a></li><li><a class="nounderline abstract_t">Frye MA, Amchin J, Bauer M, et al. Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. Int J Bipolar Disord 2015; 3:34.</a></li><li><a class="nounderline abstract_t">Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord 2015; 181:87.</a></li><li><a class="nounderline abstract_t">Yorguner Kupeli N, Bulut NS, Carkaxhiu Bulut G, et al. Efficacy of bright light therapy in bipolar depression. Psychiatry Res 2018; 260:432.</a></li><li><a class="nounderline abstract_t">Sit DK, McGowan J, Wiltrout C, et al. Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry 2018; 175:131.</a></li><li><a class="nounderline abstract_t">Zhou TH, Dang WM, Ma YT, et al. Clinical efficacy, onset time and safety of bright light therapy in acute bipolar depression as an adjunctive therapy: A randomized controlled trial. J Affect Disord 2018; 227:90.</a></li><li><a class="nounderline abstract_t">Chojnacka M, Antosik-Wójcińska AZ, Dominiak M, et al. A sham-controlled randomized trial of adjunctive light therapy for non-seasonal depression. J Affect Disord 2016; 203:1.</a></li><li><a class="nounderline abstract_t">Dauphinais DR, Rosenthal JZ, Terman M, et al. Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression. Psychiatry Res 2012; 196:57.</a></li><li><a class="nounderline abstract_t">Wu JC, Kelsoe JR, Schachat C, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009; 66:298.</a></li><li><a class="nounderline abstract_t">Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry 2015; 172:950.</a></li><li><a class="nounderline abstract_t">McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 2015; :CD011611.</a></li><li><a class="nounderline abstract_t">Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014; 231:3663.</a></li><li><a class="nounderline abstract_t">Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67:793.</a></li><li><a class="nounderline abstract_t">Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71:939.</a></li><li><a class="nounderline abstract_t">Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ 2022; 376:e067194.</a></li><li><a class="nounderline abstract_t">Stamm TJ, Lewitzka U, Sauer C, et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014; 75:162.</a></li><li><a class="nounderline abstract_t">Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry 1986; 21:915.</a></li><li><a class="nounderline abstract_t">Alda M, McKinnon M, Blagdon R, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry 2017; 210:54.</a></li><li><a class="nounderline abstract_t">Pittas S, Theodoridis X, Haidich AB, et al. The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials. Psychopharmacology (Berl) 2021; 238:1729.</a></li><li><a class="nounderline abstract_t">Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64:468.</a></li><li><a class="nounderline abstract_t">Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73:81.</a></li><li><a class="nounderline abstract_t">Appleton KM, Sallis HM, Perry R, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015; :CD004692.</a></li><li><a class="nounderline abstract_t">Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56:54.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161:564.</a></li><li><a class="nounderline abstract_t">Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 2016; 208:78.</a></li><li><a class="nounderline abstract_t">Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23:87.</a></li><li><a class="nounderline abstract_t">Husain MI, Chaudhry IB, Khoso AB, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry 2020; 7:515.</a></li><li><a class="nounderline abstract_t">Geddes JR, Gardiner A, Rendell J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 2016; 3:31.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Subramaniapillai M, Lee Y, et al. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76:783.</a></li><li><a class="nounderline abstract_t">Saricicek A, Maloney K, Muralidharan A, et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:744.</a></li><li><a class="nounderline abstract_t">McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol 2015; 30:6.</a></li><li><a class="nounderline abstract_t">Brown ES, Park J, Marx CE, et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology 2014; 39:2867.</a></li></ol></div><div id="topicVersionRevision">Topic 115481 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044195" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The long-term natural history of the weekly symptomatic status of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854249" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prediction and prevention of suicide in bipolar disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570496" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076541" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychotic features in bipolar and unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388529" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330897" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099397" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26330288" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933099" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29268206" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of bright light therapy in bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28969438" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053981" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical efficacy, onset time and safety of bright light therapy in acute bipolar depression as an adjunctive therapy: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27267951" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A sham-controlled randomized trial of adjunctive light therapy for non-seasonal depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424890" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19358978" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423481" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26415966" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038867" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ketamine administration in depressive disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679587" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22297150" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35110300" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345793" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3091097" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284082" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33641060" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534556" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903025" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26537796" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Omega-3 fatty acids for depression in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15219473" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14992985" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999335" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172906" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445690" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687300" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31066887" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21034692" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25340384" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24917198" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
